You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 5,604,131

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,604,131

Title:	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
Abstract:	A nucleic acid construct is described which when expressed in cells, results in the production of APP695, APP751 and APP770. The construct is the cDNA for APP770 with the genomic sequences encoding the KI and OX-2 regions substituting for those regions present in the cDNA.
Inventor(s):	Wadsworth; Samuel (Shrewsbury, MA), Snyder; Benjamin (Worcester, MA), Reddy; Vermuri B. (Westborough, MA), Wei; Chamer (Westborough, MA)
Assignee:	Athena Neurosciences, Inc. (South San Francisco, CA)
Application Number:	08/123,702
Patent Claims:	1. A nucleic acid construct comprising a mammalian promoter operatively linked to a cDNA-genomic DNA hybrid sequence, wherein said hybrid sequence contains a cDNA sequence encoding APP770 or a cDNA sequence encoding APP770 with a naturally occurring mutation, wherein a genomic APP DNA sequence consisting of exon 6 and an amount of the adjacent downstream intron sufficient for splicing, the KI and OX-2 coding region and an amount of each of their upstream and downstream introns sufficient for splicing, and exon 9 and an amount of the adjacent upstream intron sufficient for splicing is substituted into the corresponding region of the cDNA sequence encoding APP770, or the cDNA encoding APP770 with a naturally occurring mutation, and wherein the construct is transcribed and differentially spliced in mammalian cells to form mRNA molecules which encode and are translated into APP695, APP751 and APP770. 2. The construct of claim 1 wherein the promoter is selected from the group consisting of the human APP promoter, metallothionine promoter, rat neuron specific enolase promoter and human platelet derived growth factor B chain promoter. 3. The construct of claim 1 wherein the promoter regulates expression of the hybrid sequence in a rodent.

Details for Patent 5,604,131

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2014-02-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2014-02-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2014-02-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.